Cargando…
The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results
BACKGROUND: Even in the novel immunotherapy era, Merkel cell carcinoma (MCC) remains challenging in its treatment. Apart from Merkel cell polyomavirus (MCPyV) associated MCC, this cancer is linked in about 20% of cases to ultraviolet-induced mutational burden frequently causing aberrations in Notch...
Autores principales: | Gambichler, Thilo, Majchrzak-Stiller, Britta, Peters, Ilka, Becker, Jürgen C., Strotmann, Johanna, Abu Rached, Nessr, Müller, Thomas, Uhl, Waldemar, Buchholz, Marie, Braumann, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423113/ https://www.ncbi.nlm.nih.gov/pubmed/37311987 http://dx.doi.org/10.1007/s00432-023-04960-3 |
Ejemplares similares
-
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study
por: Baron, Claudia, et al.
Publicado: (2022) -
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo
por: Buchholz, Marie, et al.
Publicado: (2022) -
GP‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells
por: Majchrzak‐Stiller, Britta, et al.
Publicado: (2023) -
In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes
por: Gambichler, Thilo, et al.
Publicado: (2023) -
Model for End-Stage Liver Disease Correlates with Disease Relapse and Death of Patients with Merkel Cell Carcinoma
por: Gambichler, Thilo, et al.
Publicado: (2023)